Cargando…
MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies
The MDM2 gene is amplified in dedifferentiated liposarcoma (DDLPS). Treatment with MDM2 antagonists is a promising strategy to treat DDLPS; however, drug resistance is a major limitation when these drugs are used as a single agent. This study examined the impact of MDM2 antagonists on the mitogen-ac...
Autores principales: | Roy, Shomereeta, Laroche-Clary, Audrey, Verbeke, Stephanie, Derieppe, Marie-Alix, Italiano, Antoine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465494/ https://www.ncbi.nlm.nih.gov/pubmed/32806555 http://dx.doi.org/10.3390/cancers12082253 |
Ejemplares similares
-
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
por: Laroche-Clary, Audrey, et al.
Publicado: (2017) -
MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas
por: Laroche, Audrey, et al.
Publicado: (2017) -
Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting
por: Dadone-Montaudié, Bérengère, et al.
Publicado: (2020) -
Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
por: Traweek, Raymond S., et al.
Publicado: (2022) -
Intraperitoneal dedifferentiated liposarcoma showing MDM2 amplification: case report
por: Grifasi, Carlo, et al.
Publicado: (2013)